Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.

Michael K.K. Wong,Michael A. Morse,David F. McDermott,Joseph I. Clark,Howard L. Kaufman,Gregory A. Daniels,Janice P. Dutcher,Jessica C. Perritt,Hong Hua,Tharaknath Rao

Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.

2016

Michael K.K. Wong
Michael A. Morse
David F. McDermott
Joseph I. Clark
Howard L. Kaufman
Gregory A. Daniels
Janice P. Dutcher
Jessica C. Perritt
Hong Hua
Tharaknath Rao

e21039Background: High-dose interleukin-2 (HD IL-2) and immune checkpoint inhibitors can provide survival benefit in patients with metastatic melanoma (mM). The clinical impact of using these thera...

Keywords:

Melanoma
Pathology
Blockade
Cancer research
Medicine
Immune checkpoint
metastatic melanoma
survival benefit
overall survival
Oncology
initial treatment
in patient
Internal medicine
immune checkpoint inhibitors

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations